arrow
V

Vincent Barlogis

aix-marseille université
H指数:38
被引数:6,211

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Childhood isolated C3d-positive AIHA: favorable prognosis but rare relapse or associated immunodeficiency

儿童孤立性C3d阳性AIHA:预后良好,但复发或相关免疫缺陷罕见

2025-10-240
OAAI
Azathioprine or mycophenolate mofetil for pediatric autoimmune cytopenia: A propensity score-matched study

硫唑嘌呤或霉酚酸吗啉酯治疗儿童自身免疫性血细胞减少症:一项倾向性评分匹配研究

2025-10-210
OAAI
Comorbidities in Mild WAS/XLT Require Lifelong Follow-Up and Consideration of Definitive Treatment

轻度WAS/XLT的合并症需要终身随访和考虑确定性治疗

2025-09-080
OAAI
Case Report: Activated PI3-kinase-δ syndrome and ovarian malignancies: a case series from the European ESID-APDS registry

病例报告:激活的PI3-kinase-δ综合征与卵巢恶性肿瘤:来自欧洲ESID-APDS注册登记的病例系列

2025-04-300
OA
Clinical manifestations, disease penetrance, and treatment in individuals with SOCS1 insufficiency: a registry-based and population-based study

SOCS1缺乏个体的临床表现、疾病外显率及治疗:一项基于注册和人群的研究

2025-02-010
OAAI
2q33 Deletions Underlying Syndromic and Non-syndromic CTLA4 Deficiency
2024-11-230
PRE
Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome
2024-04-230
OAAI
JAK inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID/EBMT-IEWP retrospective study
2024-01-0115
PRE
Germline mutations in a G protein identify signaling cross-talk in T cells

G蛋白配体生殖系突变确定了T细胞中的信号交叉对话

Science
IF45.8
2024-01-010
OA
Activated phosphoinositide 3-kinase d syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity

活化的磷酸肌醇3-激酶d综合征: 来自ESID注册表的更新以及与其他自身免疫-淋巴增生先天性免疫错误的比较

2023-10-0116
OAAI
Impact of Graft Function on Health Status and Quality of Life in Very Long-Term Survivors Who Received an HSCT for Inborn Errors of Immunity, a Prospective Study of the CEREDIH
2023-09-013
OAAI
Impact of age at diagnosis, sex, and immunopathological manifestations in 886 patients with pediatric chronic immune thrombocytopenia

886例儿童慢性免疫性血小板减少症患者的诊断年龄,性别和免疫病理表现的影响

2023-03-218
OA
Prospective Evaluation of the First Option, Second-Line Therapy in Childhood Chronic Immune Thrombocytopenia: Splenectomy or Immunomodulation
2021-04-012
OAAI
Improving the diagnostic efficiency of primary immunodeficiencies with targeted next-generation sequencing
2021-02-0117
OAAI
Long term follow-up of pediatric-onset Evans syndrome: broad immunopathological manifestations and high treatment burden
2021-01-1418
OAAI